Key points are not available for this paper at this time.
In conclusion, CRLS1 ameliorates insulin resistance, hepatic steatosis, inflammation, and fibrosis during the pathological process of NASH by inhibiting the expression and activity of ATF3.
Tu et al. (Tue,) studied this question.